NEXGEL
Langhorne, Pennsylvania, United States · Biotechnology, Health Care
Nexgel is a company focused on developing and commercializing innovative hydrogel products. They specialize in regenerative biomaterials and have a range of products in various stages of development. The company aims to enhance patient care with their advanced biomaterial solutions. Nexgel is publicly traded under the ticker symbol NXGL.
Key facts
- Headquarters
- Langhorne, Pennsylvania, United States
- Employees
- 7
- Industries
- Biotechnology, Health Care
- Status
- Public (NXGL)
- Website
- nexgel.com
- Company page
Recent activity at NEXGEL
- : SEC 8-K (1.01): On November 10, 2026, NexGel, Inc. entered into Note Amendment and Conversion Agreements with holders of its convertible promissory notes representing approximately $14.125 million. Additionally, the Company engaged in a Securities Purchase Agreement for a private placement of common stock and warrants. These transactions are part of a broader recapitalization plan aimed at a strategic merger with Fountainhead LifeSciences and its affiliates, which is considered a related party transaction due to involvement of the Company's Interim CEO, Brian Kieser. The transactions and proposed merger are contingent upon further board approvals and the completion of specific conditions.
- : SEC 8-K (7.01): On September 24, 2026, NexGel, Inc. initiated a new shareholder update presentation titled 'Strategic Review & Proposed Platform Reorganization'. This presentation outlines the company’s strategic direction and proposed changes to its platform, which could impact its operational focus and future direction. The filing includes Exhibit 99.1, detailing this strategic initiative, although it has been noted that the information provided is not deemed 'filed' for regulatory purposes, indicating that it serves primarily as a disclosure to inform investors and stakeholders of the company's evolving strategy.
- : SEC 8-K (5.07): On September 23, 2026, NexGel, Inc. held its 2026 Special Meeting of Stockholders where stockholders voted on three proposals affecting the company's governance. A total of 6,200,043 shares of common stock were represented at the meeting, out of 9,747,663 shares entitled to vote, which constituted a quorum. The proposals discussed were previously detailed in a definitive proxy statement filed on August 24, 2026. This event marks significant engagement from shareholders and may impact future company decisions and direction.
- : NEXGEL, INC. Announces Termination of CEO Adam R. Levy
- : SEC 8-K (5.02): On August 21, 2026, NexGel, Inc. terminated Adam R. Levy's employment as Chief Executive Officer without Cause, as defined in his Executive Employment Agreement dated July 23, 2026. Following this termination, Mr. Levy also resigned from the Board of Directors and from all other officer and director positions within the company and its subsidiaries. The decision signifies a significant management change that may impact the company's strategic direction and operations. Details regarding any severance or compensatory arrangements related to this termination have not been disclosed in the filing.
- : SEC 8-K (5.02):
- : SEC 8-K (8.01): On July 9, 2026, NexGel, Inc. decided to postpone its previously scheduled 2026 Annual Meeting of Stockholders from July 10, 2026, to July 31, 2026. This decision was made to allow more time to solicit proxies from stockholders to secure the necessary votes on certain proposals set to be discussed. The record date for voting remains unchanged, allowing existing stockholders to vote at the postponed meeting, and all previously submitted proxies will still be valid unless revoked. The agenda for the meeting will remain as outlined in the Proxy Statement filed on June 9, 2026, ensuring continuity and transparency for stockholders.
- : SEC 8-K (5.02): On June 29, 2026, Scott Henry informed NexGel, Inc. of his decision to resign from the Board of Directors, effective July 1, 2026. Mr. Henry held important roles as the Chairperson of the Audit Committee and as a member of both the Compensation Committee and the Nominating and Corporate Governance Committee. His resignation was attributed to personal reasons and a desire to focus on other business ventures, and it did not involve any disagreements with the Company. This leadership change highlights potential shifts in the corporate governance structure and the need for strategic continuity in the Board's operations.
- : SEC 8-K (7.01): On June 17, 2026, NexGel, Inc. initiated a new investor presentation, which is attached as Exhibit 99.1. This move is part of their ongoing efforts to engage with investors more effectively and provide updated insights into the company's operations and future prospects. The filing indicates that this information is furnished and will not be considered 'filed' under the Securities Exchange Act, thereby protecting the company from certain liabilities related to the content of the presentation. The strategic implications suggest a proactive approach to investor relations, aiming to strengthen investment interest and market confidence.
- : Nexgel completes acquisition of BioNX
NEXGEL funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2021 | Seed | $1.6M |
| Mar 2021 | Seed | $515K |
| Mar 2021 | Seed | $1.5M |
| Aug 2020 | Seed | $395K |
| Sep 2019 | Pre-Seed | $175K |
Leadership
- Adam Levy, Executive Officer, Director
- David Stefansky, Director
- Nachum Stein, Director
- Jerome Zeldis, Director
- Steven Glassman, Director
Verified email and direct lines for NEXGEL’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
NEXGEL files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
NEXGEL in the news
- NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical - GlobeNewswire (May 13, 2026)
- NEXGEL Announces Dial-In Details for Investor Update Call - GlobeNewswire (Sep 23, 2026)
- NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE - GlobeNewswire (Aug 20, 2026)
- NEXGEL Reports Second Quarter 2026 Financial Results - GlobeNewswire (Aug 17, 2026)
- NEXGEL Announces 1-for-20 Reverse Stock Split Effectiveness - GlobeNewswire (Oct 12, 2026)
- NEXGEL Announces Date for Investor Update Call - GlobeNewswire (Sep 16, 2026)
- NEXGEL Regains Compliance with Nasdaq Listing Requirement - GlobeNewswire (Oct 27, 2026)
- NEXGEL New Strategic Partner, Sequence LifeScience™, Leads - GlobeNewswire (Apr 21, 2026)
Companies similar to NEXGEL
- naturemary · Biotechnology, Health Care
- TransCode Therapeutics · Biotechnology, Health Care
- Eascra Biotech · Biotechnology, Health Care
- Molecular Targeting Technologies · Biotechnology, Health Care
- EnVision Endoscopy · Biotechnology, Health Care
About NEXGEL: questions and answers
What does NEXGEL do?
Nexgel is a company focused on developing and commercializing innovative hydrogel products. They specialize in regenerative biomaterials and have a range of products in various stages of development. The company aims to enhance patient care with their advanced biomaterial solutions. Nexgel is publicly traded under the ticker symbol NXGL.
Where is NEXGEL headquartered?
NEXGEL is headquartered in Langhorne, Pennsylvania, United States.
How many employees does NEXGEL have?
NEXGEL has about 7 employees.
Has NEXGEL raised funding?
Yes. Fundz has recorded 5 funding events for NEXGEL. The most recent, Seed of $1.6M, was in Sep 2021.
What is the latest news on NEXGEL?
On Nov 12, 2026, SEC 8-K (1.01): On November 10, 2026, NexGel, Inc. entered into Note Amendment and Conversion Agreements with holders of its convertible promissory notes representing approximately $14.125 million. Additionally, the Company engaged in a Securities Purchase Agreement for a private placement of common
Is NEXGEL a public company?
Yes. NEXGEL is publicly traded under the ticker NXGL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy